The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.
Epistemonikos ID: 5804105886167ec1a6503956f38d91bab1826feb
First added on: May 07, 2024